Avatar Posted by worldpharmanews 392 days ago (http://www.worldpharmanews.com)
Category: Product | Tags: amgen denosumab
Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has accepted Amgen's submission and filed a Biologics License Application (BLA) for denosumab, an investigational RANK Ligand inhibitor. The indications for which Amgen is seeking FDA approval are treatment and prevention of postmenopausal osteoporosis (PMO) in women and treatment and prevention of bone loss in patients undergoing hormone ablation therapy for either prostate or breast cancer.
Discuss   Add this link to...  Bury

Comments Who Voted Related Links


News/Blogroll [ alliConnect | BioJobBlog | Central and Eastern Europe Pharma | CNTO411 | Corey Nahman | eDrugSearch | Drug Injury Watch | EyeOnFDA | Forbes ScienceBiz | Healthy Skepticism | JNJ BTW | medGadget | Medical 2.0 | Pharma's Market at CNBC | PharmaFraud | PharmaGossip | Pharmalot | PharmaNews.eu | Polish Pharma Market | The Shark Report | World Pharma News | WSJ Health Blog ]
Pharmaceutical Companies [ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

About | Buttons | Contact | Terms and Conditions
Concept and Design by World Pharma News (.com) Project | Powered by Pligg based on PHP/MySQL.
Submit to World Pharma News .net